Celecoxib

For research use only.

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

35 publications

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 420 In stock
USD 70 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Celecoxib has been cited by 35 publications

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NWLUOZdsTnWwY4Tpc44hSXO|YYm= MkTVNE4yNTNyIN88US=> NYXhUphpPDhiaB?= MljIbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> M4f5e|I3PTF|MUey
H460 NXnHblRyTnWwY4Tpc44hSXO|YYm= NHP4ZWgxNjFvM{Cg{txO M4HRXFQ5KGh? NVvYOoFkcW6mdXPld{BKS0GPLUGg[ZhxemW|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx? NGDCN|MzPjVzM{G3Ni=>
HKESC-2 NFTWdlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYmyNOKh|ryP MV[0POKhcMLi M4HuZ5Nq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? NHOzTlgzPjR5NE[5Ny=>
CaES-17 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILUO|UzOMLizszN MYe0POKhcMLi NUThVmJ3e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi MViyOlQ4PDZ7Mx?=
HKESC-2 Mn:2RZBweHSxc3nzJGF{e2G7 M{fhd|IxyqEQvF2= NE[weZk1QMLiaNMg NHu1TmNz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ M4H5[|I3PDd2Nkmz
CaES-17 MX3BdI9xfG:|aYOgRZN{[Xl? NYfhU4N2OjEEoN88US=> NF3C[nU1QMLiaNMg NYTucppremWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>? M{i4fVI3PDd2Nkmz
A549 Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXi1MVE3OCEQvF2= NHK5eJM1QMLiaNMg NWrEZnhDTE2VTx?= NYHVboM2UUN3ME2xOlMvPCEQvF2= MXmyOlQ3PDZ2Mx?=
HCC827 M{X6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy1MVE3OCEQvF2= Ml7BOFjDqGkEoB?= MlrsSG1UVw>? NXHTZnp7UUN3ME22PU4zKM7:TR?= Ml7FNlY1PjR4NEO=
A549 MonMRZBweHSxc3nzJGF{e2G7 MkjMPFAhyrWP M{T6bVQ5yqCqwrC= MUfEUXNQ NYTHfVdQcW6mdXPld{BieG:ydH;zbZM> Mmr0NlY1PjR4NEO=
HCC827 MlLQRZBweHSxc3nzJGF{e2G7 MY[4NEDDvU1? NIO1eZA1QMLiaNMg NX61cZNZTE2VTx?= NFLLbodqdmS3Y3XzJIFxd3C2b4Ppdy=> Mn\XNlY1PjR4NEO=
SGC-7901/DDP MU\GeY5kfGmxbjDBd5NigQ>? NUX2WWp1OTEEoNM1US=> NHTKfHAzPCCq NHTDXY1qdmirYnn0d{BkgWOub3;4fYdmdmG|ZT2yJIFv\CCSLXfsfYNweHKxdHXpckBmgHC{ZYPzbY9v MnvYNlY1ODd4NUO=
SGC-7901  Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTBUI1HOjUEoHlCpC=> MXTJR|UxRTFzNT6wPEDPxE1? NV7nflk6OjZ2MEe2OVM>
SGC-7901/DDP M4TWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqyOOKhcMLi NInQSGFKSzVyPUO1MlQ2KM7:TR?= MYWyOlQxPzZ3Mx?=
SGC-7901/DDP M2rZVGFxd3C2b4Ppd{BCe3OjeR?= NX;EeJc{OTEEoNM1US=> M1;BOlI1KGh? M1vQZolv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhid3n0bEBkcXOybHH0bY4> NIGxbJAzPjRyN{[1Ny=>
SGC-7901/DDP MUHGeY5kfGmxbjDBd5NigQ>? NWHtR5V7OTEEoNM1US=> MWiyOEBp MkfnbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gVE1odHmlb4Dyc5RmcW5idHjyc5VocCCkbH;jb4lv\yCHUEKsJIFv\CCrbnHjeIl3[XSrbnegVGtCKGGwZDDDVmVDyqB? MmXXNlY1ODd4NUO=
SGC-7901/DDP M2TLTGZ2dmO2aX;uJGF{e2G7 NFfHSI4yOMLiwsXN NVj4WJhrOjRiaB?= NV\r[HV1[2G3c3XzJIEhdWG{a3XkJIRm[3KnYYPlJIlvKHSqZTDs[ZZmdCCxZjDCZ4wuOiCycn;0[Ylv MnPFNlY1ODd4NUO=
H357 NYPvW5JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;DZlcvPS9zMDFOwG0> NVXyfpFIPDhiaB?= MmrnSG1UVw>? M3uxUYlvcGmkaYTzJINmdGxiZ4Lve5RpyqClb33ibY5m\CC5aYToJHNi[nW2b3PsZZg> M2nHRlI3ODB7OEe0
TAF MYDGeY5kfGmxbjDBd5NigQ>? M3SzPFExyqEEtV2= Mn\uO{Bl MmfhZYZn\WO2czDURWZ{KGGmaHXzbZZmKHC{b4DldpRq\XN? MX[yOVk5PzF{Nx?=
TAF NFfLbmZHfW6ldHnvckBCe3OjeR?= M1jyXFExyqEEtV2= NFLoWlc{OC1zMkCgcYlv MmrUdI9wemy7IHHm[oVkfHNiZFHreEBxcG:|cHjvdplt[XSrb36gZ49ve2WzdXXueEB1dyCHR1[gd4lodmGuaX7n NF7rb2czPTl6N{GyOy=>
TAF M3z6NWZ2dmO2aX;uJGF{e2G7 MV:xNOKhyrWP MoPLOFghcA>? MYDpcoNz\WG|ZYOgSWdHWiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NV7YZZpQOjV7OEexNlc>
PANC-1 M2L6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXC[|YzOC94MD:xNFAh|ryP MUCyOE81QC95MjDo NIXmfJVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NFPLUHEzPTl5M{C2Ni=>
PANC-1 NV3STIw1TnWwY4Tpc44hSXO|YYm= MXWyNE83OC9zMECg{txO NEP4VGEzPCCq MXfheJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA> MofWNlU6PzNyNkK=
HeLa  MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET3ZXYzOMLizszNxsA> M{Lpb|I1yqCq M1nCZoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w MVOyOVc4ODR{Mx?=
SACC-83 NYj5[Zc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zRelIxyqEQvF5CpC=> M2rE[FI1yqCq MVnlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? MX:yOVc4ODR{Mx?=
HeLa  M2fzV2Fxd3C2b4Ppd{BCe3OjeR?= NGPQUVYzOMLizszNxsA> MmHqNlTDqGh? MYjlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz M3\aS|I2PzdyNEKz
SACC-83 NGq2NZRCeG:ydH;zbZMhSXO|YYm= MnLONlDDqM7:TdMg Mnj5NlTDqGh? NUjTdFBi\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>? MmLlNlU4PzB2MkO=
HeLa  MkDHSpVv[3Srb36gRZN{[Xl? M33rUlIxNzRyL{iwJO69VQ>? MnLDNlTDqGh? Mly0eZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q> M{fIb|I2PzdyNEKz
SACC-83 MoLpSpVv[3Srb36gRZN{[Xl? MYqyNE81OC96MDFOwG0> MVKyOOKhcA>? MYj1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> M4jPNVI2PzdyNEKz
HLCZ01 MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn1cnkx6oDVNkFCpOK2VQ>? MX60PEBp M3rBWmROW09? M2riO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NX;mTFkyOjV5MkS4PVk>
HLCZ01 NH\JV2pHfW6ldHnvckBCe3OjeR?= NHfyW4k1OMLizszN M{TKc|I1KGh? NHvsPJRFVVOR MWrpcoNz\WG|ZYOgZYNkfW23bHH0bY9vKG:oIFewM2cyNXCqYYPlJINmdGy|IHPvcYJqdmWmIIfpeIghUU[QLd8x M{C0ZVI2PzJ2OEm5
HLCZ01 NHztV2ZCeG:ydH;zbZMhSXO|YYm= NHjmXWI1OMLizszN MVGyOEBp MmPBSG1UVw>? M3TiT4VvcGGwY3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>? MkDrNlU4OjR6OUm=
HLCZ01 M{HsTmZ2dmO2aX;uJGF{e2G7 M{nlTVQxyqEQvF2= MkDWNlQhcA>? NY[wdpI1TE2VTx?= NGnhUGtqdmO{ZXHz[ZMhXFKDSVyg[ZhxemW|c3nvckBkd22kaX7l[EB4cXSqIFnueIVz\mW{b36t{tE> M3vCTVI2PzJ2OEm5
MGC803 NVXZR3g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHMNE03OCEQvF2= MmTwO|IhcA>? MnrZTWM2OD12Nz6yOgKBkcLz4pEJOk41OyEQvF2= MkfWNlU4ODF|N{i=
SGC7901 Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn1NE03OCEQvF2= NY[x[lZtPzJiaB?= NUPWU29FUUN3ME20N{42O+LCidMx5qCKPS5zMjFOwG0> MnvGNlU4ODF|N{i=
MGC803 NUPoXnhMTnWwY4Tpc44hSXO|YYm= NH;XWWQ1OMLizszN Ml7sPE8yPi9{NDDo M{PlZ5VxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> NYXCOGNPOjV5MEGzO|g>
SGC7901 MoXTSpVv[3Srb36gRZN{[Xl? NHnucGc1OMLizszN MYK4M|E3NzJ2IHi= M1L2N5VxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> NHTWZWQzPTdyMUO3PC=>
MCF-7  MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vxcFEwOTBizszN Ml3jO|IhcA>? NYnBS3R{TE2VTx?= MYTlcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>? MWKyOVY3PzVzMB?=
MDA-MB-231  MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTiU5MyNzFyIN88US=> NGrHVoE4OiCq NGPYcmpFVVOR MmDq[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? NYLBPGVKOjV4Nke1NVA>
MDA-MB-231 MVTGeY5kfGmxbjDBd5NigQ>? MUWwMVQxKML3TR?= NUHSb|lzPC1{NDDo NIDLcZdqdmO{ZXHz[ZMhS0:[LUKgdJJwfGWrbjDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnRibXHucoVz MYKyOVU5PzN{OR?=
MCF-7 NEHrdnBHfW6ldHnvckBCe3OjeR?= NF\rO4gxNTRyINM1US=> MoLyOE0zPCCq MlHl[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? MUOyOVU5PzN{OR?=
MCF7-MX  NHH6WHpHfW6ldHnvckBCe3OjeR?= NYHJSGhIOC12MDFCuW0> Mn;TOE0zPCCq M3;CRYVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? M3vKSlI2PTh5M{K5
MDA-MB-231 NWPORml2TnWwY4Tpc44hSXO|YYm= MnzhNE01OCEEtV2= NILURmo1NTJ2IHi= M2XzVZN1cW23bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhSUKFR{KgeZAhfG9iND6yO{B1cW2nczD0c{Bkd262cn;sJIxmfmWuIHL5JFEzKGkEoB?= NH;wbWIzPTV6N{OyPS=>
A2780 M375V2Z2dmO2aX;uJGF{e2G7 NYHIRoR6PS9zMD:xOUDPxE1? MojvOFghcA>? Mkjy[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnrxNlU1OjR6OUi=
SKOV3  NHvHXXhHfW6ldHnvckBCe3OjeR?= NGS1VHc2NzFyL{G1JO69VQ>? NVTSUHRJPDhiaB?= M{\5eIRm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVSyOVQzPDh7OB?=
A2780 NVnzdnF1TnWwY4Tpc44hSXO|YYm= MXK1M|ExNzF3IN88US=> NGTScok1QCCq MkPY[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>? MoKwNlU1OjR6OUi=
SKOV3  MnrPSpVv[3Srb36gRZN{[Xl? Mn35OU8yOC9zNTFOwG0> MlzjOFghcA>? MWDlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv NFXSVnAzPTR{NEi5PC=>
A2780 M1\4UGZ2dmO2aX;uJGF{e2G7 NWDNWIVoPS9zMD:xOUDPxE1? NHLZdnc1QCCq NUjnNZVo\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu NYDzWG9LOjV2MkS4PVg>
SKOV3  M2jCNGZ2dmO2aX;uJGF{e2G7 MmXBOU8yOC9zNTFOwG0> MYi0PEBp NXfsfJFX\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu NETwRWYzPTR{NEi5PC=>
A2780 MlywSpVv[3Srb36gRZN{[Xl? MkDhOU8yOC9zNTFOwG0> Mof5NUBp M{PMOIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MUKyOVQzPDh7OB?=
SKOV3  NXXjVJBZTnWwY4Tpc44hSXO|YYm= NFS4VFE2NzFyL{G1JO69VQ>? NG\oSngyKGh? MVPpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYOyOVQzPDh7OB?=
HCT-15 NELjbW1HfW6ldHnvckBCe3OjeR?= MlS3NVAuPTBizszN M4Hh[|YuOzZiaB?= MnywbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NELxcVIzPTJzOECyPC=>
HT-29  NXvue2tWTnWwY4Tpc44hSXO|YYm= NXvINGdkOTBvNUCg{txO NFq2UY03NTN4IHi= Mn7ubY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= MXOyOVIyQDB{OB?=
HSC3  MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHf5bGIx6oDVNECg{txO MmPuOFghcA>? NUm3T4Z2UUN3ME2yOU42yrFzLke4NEDPxE1? MoLvNlUyQTh5OEm=
HSC3  M2DZZmFxd3C2b4Ppd{BCe3OjeR?= M3r6NVI2KM7:TR?= M{SyVlQ5KGh? M1;ld4lv\HWlZYOgZZBweHSxc3nz M4Lwd|I2OTl6N{i5
HSC3  MULGeY5kfGmxbjDBd5NigQ>? MlnGNlUh|ryP M2LqcVQ5KGh? MYnlfIhq[mm2czDzbYdvcW[rY3HueIx6KHKnZIXj[YQhdWmpcnH0bY9vKGOxbXLpcoVlKHerdHigR2VV NX64XYdDOjVzOUi3PFk>
HSC3  NGr1[oxHfW6ldHnvckBCe3OjeR?= MkOyNlUh|ryP NVu4epd4PDhiaB?= NXq1NYM3cW6qaXLpeJMhUFOFMzDj[YxtKGmwdnHzbY9vKGOxbXLpcoVlKHerdHigR2VV NIXWd5MzPTF7OEe4PS=>
HSC3  NYryUVRkTnWwY4Tpc44hSXO|YYm= MX[yOUDPxE1? NFX0O204OiCq NELJRpdl\WO{ZXHz[ZMhVU2SLUKgZY5lKE2PUD25JJBzd3SnaX7zxsA> MkTmNlUyQTh5OEm=
201T  M1HUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7oWHU4OiCq NUDwXHhKTE2VTx?= M1qzPWlEPTB;NEiuOkDDvU1? M{LSS|I2ODV5OUSx
273T MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXLW49YPzJiaB?= MnLxSG1UVw>? MUDJR|UxRThyLkWgxtVO M1;HTVI2ODV5OUSx
Hep-2 NXzyXZRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGzNE82OC9zMECg{txO MV2xNk8zPC9|Nj:0PEBp NUnHSlJJTE2VTx?= NULGPXhEcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NHTSU3EzPDl7OEW2OC=>
Hep-2 NWjMV484SXCxcITvd4l{KEG|c3H5 MVO1NEDPxE1? NGLVd|gxNTR6IHi= NHvjOYNFVVOR Mo\sbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NV30eoRVOjR7OUi1OlQ>
Hep-2 M3rJOmZ2dmO2aX;uJGF{e2G7 NH\JVIU2OCEQvF2= NHPYUm4xNTR6IHi= MoPZSG1UVw>? MmridoVlfWOnczD0bIUhfGWub33ldoF{\SCjY4Tpeol1gSCpcnHkeYFtdHl? MnjrNlQ6QTh3NkS=
Hep-2 M4fIR2Z2dmO2aX;uJGF{e2G7 MWO1NEDPxE1? M{n0WlAuPDhiaB?= NIS5bJpFVVOR M{XCPYRm[3KnYYPld{B1cGVibWLORUBmgHC{ZYPzbY9vKG:oIHjUSXJV MkTzNlQ6QTh3NkS=
SGC-7901 NFK0bWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i4WVExNzVyL{GwNEDPxE1? Moj4NlQwPDhxN{KgbC=> NVizVHB7TE2VTx?= NWjteVNXcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= Mn\iNlQ6QTJ7NUi=
MKN-45 NY\rXnQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfHSoJ7OTBxNUCvNVAxKM7:TR?= M{jZcFI1NzR6L{eyJIg> NF;zcFZFVVOR MkDYbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NG\EU2wzPDl7Mkm1PC=>
SGC-7901 NEnuN2RHfW6ldHnvckBCe3OjeR?= M3TtU|ExNzVyL{GwNEDPxE1? MnvYOFghcA>? NFq1W5hFVVOR Mnjw[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NU\SRXdlOjR7OUK5OVg>
MKN-45 MnH1SpVv[3Srb36gRZN{[Xl? NX\DS|RQOTBxNUCvNVAxKM7:TR?= NIrKWGM1QCCq MWHEUXNQ Mlzx[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M1LUR|I1QTl{OUW4
C666-1 NF:1PGVEgXSxdH;4bYNqfHliQYPzZZk> M3y1b|IxNThyIN88US=> M2rTR|I1KGh? NX[wTG1k\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? MXOyOFg2PDh|OB?=
CNE-1 MVLDfZRwfG:6aXPpeJkhSXO|YYm= NWLXV4p5OjBvOECg{txO NWrTUHFzOjRiaB?= Mmqy[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> NFLnRpozPDh3NEizPC=>
CNE-2 MULDfZRwfG:6aXPpeJkhSXO|YYm= NXPmeZZ2OjBvOECg{txO MnnwNlQhcA>? MUTk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg NUDIblR3OjR6NUS4N|g>
C666-1 NUTlSol3S3m2b4TvfIlkcXS7IFHzd4F6 NX;KVIdjPjBizszN M1rre|ch\A>? NYOxbIZ1\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> NYq0dmhEOjR6NUS4N|g>
CNE-1 NF61V|lEgXSxdH;4bYNqfHliQYPzZZk> NED6TZg3OCEQvF2= MUO3JIQ> M{TyfoVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy MlrzNlQ5PTR6M{i=
SNU-1041 M{fQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTOfo8xNTRyIN88US=> MlL3OFghcA>? NFLJRo1qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NIjre5czPDZ7MkewNy=>
SNU-1041 MYnGeY5kfGmxbjDBd5NigQ>? MVWyNE8{OCEQvF2= NFPZTpU1KGh? NGX5XXpqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>? NUXJWJl2OjR4OUK3NFM>
SNU-1041 M2HObGZ2dmO2aX;uJGF{e2G7 MXOwMVQxKM7:TR?= NXPJVFZoPCCq M2fhZpVxNXKnZ4XsZZRmeyCFSF;QxsBi\nSncjD0doVifG2nboSge4l1cCCqaXfoJINwdmOnboTyZZRqd26| NX3WT2prOjR4OUK3NFM>
SGC-7901 MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fQRVUxNTF{NTFOwG0> M2HZTFI1NzR6L{eyJIg> M{LkV4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NILvfZIzPDZ5NkO5OC=>
SGC-7901 Moi3RZBweHSxc3nzJGF{e2G7 MVSxNFAh|ryP M{LqTlczKGh? M4XSUIlv\HWlZYOgZZBweHSxc3nz MYSyOFY4PjN7NB?=
SGC-7901 MkD4SpVv[3Srb36gRZN{[Xl? M4fC[Vc2NzFyMD:xNlUh|ryP NGLnWHAzPC92OD:3NkBp NGjzZ5ZqdmO{ZXHz[ZMh[2G|cHHz[U05KGGwZDCtPUBuWk6DIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKG2jbn7ldi=> NXjn[ZdCOjR4N{[zPVQ>
LMeC  NXzkXJAxTnWwY4Tpc44hSXO|YYm= M1vLfVIxNzVyIN88US=> MVy0PEBp NYe2Z3ZY\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEORWD2yJJBzd3SnaX6= MV[yOFY2Pjd2Nh?=
CMeC-1 MknLR4VtdCCYaXHibYxqfHliQYPzZZk> NXfwcI41OjBxNUCg{txO NIrMRW81QCCq NXjSe5JJcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NXnmcmZmOjR4NU[3OFY>
LMeC NHzL[pRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFvyOnQzOC93MDFOwG0> NI\UUnk1QCCq MWXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M{P1ZlI1PjV4N{S2
CMeC-1 M{PDUGZ2dmO2aX;uJGF{e2G7 NVzocGZROjBxNUCg{txO NWHpcHNwPDhiaB?= Mn;LbY5lfWOnczDHNU1UKGG{cnXzeC=> M1jOR|I1PjV4N{S2
LMeC MX7GeY5kfGmxbjDBd5NigQ>? NGHnZZczOC93MDFOwG0> M362fVQ5KGh? MUDpcoR2[2W|IFexMXMh[XK{ZYP0 MnLlNlQ3PTZ5NE[=
CMeC-1 M4nYTmZ2dmO2aX;uJGF{e2G7 MYeyNE82OCEQvF2= M4HWV|Q5KGh? MUPk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCleXPsbY4hTDFiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUKyOFY2Pjd2Nh?=
LMeC MXLGeY5kfGmxbjDBd5NigQ>? NWDHOJVZOjBxNUCg{txO NYPYOWpYPDhiaB?= NVToTJpM\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NV;CTGo4OjR4NU[3OFY>
CMeC-1 M4HVO2Z2dmO2aX;uJGF{e2G7 MWqyNE82OCEQvF2= M2K4UVQ5KGh? MnyxbY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> NYHhW2F{OjR4NU[3OFY>
LMeC MkDRSpVv[3Srb36gRZN{[Xl? NXXJeng{OjBxNUCg{txO MlPNOFghcA>? M{fpfIlv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> M3j3SVI1PjV4N{S2
OVCAR-3 MnOyR4VtdCCYaXHibYxqfHliQYPzZZk> MkHlNVAhyrWP MYKxJIg> NH7uN4VmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh M2f5cVI1PTJyMkK3
OVCAR-3 NH;ldopCeG:ydH;zbZMhSXO|YYm= M32xb|ExKML3TR?= MYKxJIg> MXvwdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA> MYeyOFUzODJ{Nx?=
OVCAR-3 MXvGeY5kfGmxbjDBd5NigQ>? NEXnTYgyOCEEtV2= NGO4fYkyKGh? M{PzeYVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2VvOdMg NX3VV2M2OjR3MkCyNlc>
OVCAR-3 M4e1dWZ2dmO2aX;uJGF{e2G7 NE\wPZUyOCEEtV2= MWSxJIg> MlPO[I94di2{ZXf1cIF1\XNiTl[t{tpDKGGldHn2ZZRqd25iaX7keYNm\CCkeTDwZYNtcXSjeHXs MknaNlQ2OjB{Mke=
OVCAR-3 NHficYxHfW6ldHnvckBCe3OjeR?= MmLiNVAhyrWP MnfjNUBp MYjpcohq[mm2czDwZYNtcXSjeHXsMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> MYiyOFUzODJ{Nx?=
CF33 NHvGV41HfW6ldHnvckBCe3OjeR?= MnX6NVAxKM7:TR?= NHzlT3EzPCCq MonVbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDDU3guOiCycn;0[YlvKGW6cILld5Nqd25? M1X6PFI1PTB|N{iy
CF33 NFPhO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG4O2wyOC1zMECg{txO MmDENE01KGR? M2THb4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmjENlQ2ODN5OEK=
CF33 M3HybmZ2dmO2aX;uJGF{e2G7 MUexNE0yODBizszN MnPwOE0zPCCq M1jSUYRm[3KnYYPld{Bk\WyuczDpckB1cGViUzDwbIF{\SCjbnSgbY5kemWjc3XzJINmdGy|IHnuJGcxN0dzIHHydoV{fA>? M1fpcVI1PTB|N{iy
LNCaP NX7scHR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vzdVIwPS9zMDFOwG0> MUm5OkBp NXG2U4VScW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfUBkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> M3GzZVI1Ojl4OUe4
LNCaP M13abWFxd3C2b4Ppd{BCe3OjeR?= M1PGbVIwPS9zMDFOwG0> M1;0blk3KGh? MXXpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?= NHTac2czPDJ7Nkm3PC=>
PC-3  NWT1OlRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLJNE02OCEQvF2= MlfJOFjjiImq M3O1UYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NXnFSYdMOjRzMke4PFI>
PC-3  MkTQR4VtdCCYaXHibYxqfHliQYPzZZk> NWe3RWRGOC1zMECg{txO M1r4TFczKGh? M2TwXIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MmPhNlQyOjd6OEK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Fibronectin / Vimentin / N-cadherin / E-cadherin ; 

PubMed: 28978083     


(A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells.

COX-2; 

PubMed: 29515134     


L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. 

pAKT / AKT / PPARγ / PTEN ; 

PubMed: 24721996     


Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h. 

28978083 29515134 24721996
Immunofluorescence
PPARγ / PTEN ; 

PubMed: 24721996     


Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.

24721996
Growth inhibition assay
Cell viability; 

PubMed: 28521485     


Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth. 

28521485
In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
- Collapse

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
- Collapse
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635
Smiles CC1=CC=C(C=C1)C2=CC(=N[N]2C3=CC=C(C=C3)[S](N)(=O)=O)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03896113 Recruiting Drug: Celecoxib 200mg capsule Endometrium Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain November 13 2019 Phase 2
NCT03643744 Recruiting Drug: Celecoxib 200mg|Drug: Placebo Actinic Keratosis|Photodynamic Therapy Jeffrey B. Travers MD PhD|Wright State Physicians April 1 2019 Phase 1
NCT01344200 Not yet recruiting Drug: Celecoxib Pharmacokinetics of Celecoxib in Children Children''s Hospital of Eastern Ontario March 2019 Phase 4
NCT02876094 Recruiting Drug: celecoxib Spinal Muscular Atrophy (SMA) Hugh McMillan|Families of Spinal Muscular Atrophy|Gwendolyn Strong Foundation|Children''s Hospital of Eastern Ontario January 29 2019 Phase 2
NCT03672162 Recruiting Procedure: Total abdominal hysterectomy Total Abdominal Hysterectomy Pain Acute PostoperativeGabapentin Celecoxib Rajavithi Hospital September 1 2018 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID